Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of the Male Reproductive System01:20

Disorders of the Male Reproductive System

285
Men's health issues are increasingly recognized as significant, with several conditions posing common threats. Among these, testicular cancer is especially prevalent in younger men, particularly those aged 20 to 35 years. The disease often manifests as a painless mass in the testicles, sometimes accompanied by a sensation of heaviness or a dull ache.
Prostate disorders are another major concern. These conditions can impair urinary flow due to the prostate's location around the urethra....
285

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical and racial predictors of adverse pathology at radical prostatectomy: implications for undertreatment among patients receiving radiation and hormonal therapy.

The Canadian journal of urology·2026
Same author

Postoperative Pelvic Lymph Node Radiation Therapy in Lymph Node-Positive Prostate Cancer and Mortality Risk.

European urology focus·2026
Same author

Testosterone and docetaxel treatment effect on mortality risk in nonmetastatic high-risk prostate cancer: A predictive biomarker analysis.

Cancer·2026
Same author

Surveillance Versus Treatment for Favorable Intermediate-Risk Prostate Cancer and Mortality-Risk.

The Prostate·2026
Same author

Cribriform-Positive and -Negative Prostate Cancer.

JAMA oncology·2026
Same author

Re: Alexander B.C.D. Ng, Aqua Asif, Ridhi Agarwal, et al. Biparametric vs Multiparametric MRI for Prostate Cancer Diagnosis: The PRIME Diagnostic Clinical Trial. JAMA 2025;334:1170-9.

European urology·2025
Same journal

Circulating Tumor DNA Status and Adjuvant Chemotherapy in Resected Colorectal Liver Metastases.

JAMA oncology·2026
Same journal

Cardiac Risk After Heart-Sparing Breast Radiotherapy.

JAMA oncology·2026
Same journal

When Not to Push the Boulder.

JAMA oncology·2026
Same journal

Circulating Methylated SEPT9 for Detection of Hepatocellular Carcinoma in Cirrhosis.

JAMA oncology·2026
Same journal

Less Can Be More by Circulating Tumor DNA Use in ERBB2-Positive Breast Cancer.

JAMA oncology·2026
Same journal

Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.

JAMA oncology·2026
See all related articles

Related Experiment Video

Updated: May 22, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K

Persistent Prostate-Specific Antigen Following Radical Prostatectomy for Prostate Cancer and Mortality Risk.

Derya Tilki1,2,3, Ming-Hui Chen4, Jing Wu5

  • 1Martini-Klinik Prostate Cancer Center, University Hospital Hamburg Eppendorf, Hamburg, Germany.

JAMA Oncology
|March 13, 2025
PubMed
Summary
This summary is machine-generated.

A longer assessment period of at least 3 months after radical prostatectomy (RP) may prevent overtreatment of persistent prostate-specific antigen (PSA). Higher persistent PSA levels after RP are linked to worse outcomes in prostate cancer patients.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Related Experiment Videos

Last Updated: May 22, 2025

Retzius-Sparing Robot-Assisted Radical Prostatectomy
12:10

Retzius-Sparing Robot-Assisted Radical Prostatectomy

Published on: May 19, 2022

7.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.0K
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
13:19

Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer

Published on: November 2, 2013

16.5K

Area of Science:

  • Urology
  • Oncology
  • Medical Statistics

Background:

  • The conventional 1.5 to 2.0-month interval post-radical prostatectomy (RP) for prostate cancer (PC) may not be sufficient for accurate persistent prostate-specific antigen (PSA) documentation.
  • Accurate PSA monitoring is crucial for guiding further PC treatment and assessing prognosis.

Purpose of the Study:

  • To evaluate the optimal time interval required for accurate documentation of persistent PSA levels after RP.
  • To investigate the association between pre-RP PSA levels, persistent PSA, and mortality risks after RP.

Main Methods:

  • A large cohort study analyzed data from patients treated with RP between 1992 and 2020.
  • Statistical models adjusted for known prognostic factors, age, year of RP, and post-RP therapies (radiation therapy and androgen deprivation therapy).
  • Interactions between pre-RP PSA levels and persistent PSA on mortality risks were assessed.

Main Results:

  • A pre-RP PSA level >20 ng/mL with persistent PSA was associated with reduced all-cause mortality (ACM) and PC-specific mortality (PCSM) risk compared to undetectable PSA.
  • This finding suggests that a longer assessment period might allow more patients to achieve undetectable PSA, potentially avoiding unnecessary treatments.
  • Increasing persistent PSA levels were significantly associated with increased ACM and PCSM risks.

Conclusions:

  • Assessing PSA levels for at least 3 months post-RP may help minimize overtreatment.
  • Higher persistent PSA levels after RP are correlated with a worse prognosis for prostate cancer patients.
  • These findings support a revised approach to post-RP PSA monitoring to optimize patient outcomes.